Ingredient or product comparison
AHK-Cu Hair Follicle Copper Peptide Mechanism: Comparison
Primary target Lysyl oxidase and SOD1 enzyme activation in dermal papilla Potassium channel opening in vascular smooth muscle 5α-reductase enzyme inhibition (blocks DHT synthesis) AHK-Cu targets extracellular matrix and oxidative stress; minoxidil improves blo
This source-based comparison does not add ratings or recommend a winner.
- Primary target
- Lysyl oxidase and SOD1 enzyme activation in dermal papilla
- Potassium channel opening in vascular smooth muscle
- 5α-reductase enzyme inhibition (blocks DHT synthesis)
- AHK-Cu targets extracellular matrix and oxidative stress; minoxidil improves blood flow; finasteride removes hormonal driver
- Mechanism onset
- Enzyme activation within 48–72 hours; visible hair changes 3–6 months
- Vasodilation immediate; follicle response 3–4 months
- DHT reduction within days; hair response 6–12 months
- AHK-Cu and minoxidil show similar timelines for visible results despite different mechanisms
- Follicle size impact
- Increases dermal papilla cell proliferation 230%; partial reversal of miniaturization
- Increases follicle diameter through improved perfusion
- Prevents further miniaturization; modest reversal in early-stage cases
- Finasteride addresses root cause (DHT); AHK-Cu and minoxidil support existing follicles
- Systemic effects
- None. Topical only, no systemic copper elevation
- Minimal if topical; hypotension if oral formulation
- Significant. Sexual dysfunction 1–5%, gynecomastia, mood effects
- AHK-Cu and topical minoxidil are localized; finasteride has documented systemic side effects
- Evidence level
- Multiple in vitro studies; limited clinical trial data for hair loss specifically
- FDA-approved; extensive Phase III trials
- FDA-approved; decades of clinical use and safety data
- Finasteride and minoxidil have robust clinical evidence; AHK-Cu relies on mechanistic and cell culture data